Patents Assigned to Merck Sharp
  • DIAMINO-ALKYLAMINO-LINKED ARYLSULFONAMIDE COMPOUNDS WITH SELECTIVE ACTIVITY IN VOLTAGE-GATED SODIUM CHANNELS
    Publication number: 20200131167
    Abstract: Disclosed are compounds of Formula A, or a salt thereof: Formula (A), wherein: Het, Q and R1A to R4A are defined herein, which compounds have properties for blocking Nav 1.7 ion channels found in peripheral and sympathetic neurons. Also described are pharmaceutical formulations comprising the compounds of Formula A or their salts, and methods of treating cough, itch, acute pain and neuropathic pain disorders using the same.
    Type: Application
    Filed: November 13, 2017
    Publication date: April 30, 2020
    Applicant: Merck Sharp & Dohme Corp.
    Inventors: Thomas J. Greshock, James Mulhearn, Anthony J. Roecker, Tianying Jian, Gang Zhou, Liangqin Guo, Walter Won, Ting Zhang, Rajan Anand, John E. Stelmach, Deping Wang, Ronald M. Kim, Mark E. Layton, Christopher S. Burgey, Philippe G. Nantermet
  • ANTI-CD27 ANTIBODIES
    Publication number: 20200131272
    Abstract: The present invention relates to anti-CD27 antibodies, as well as use of these antibodies in the treatment of diseases such as cancer and infectious disease.
    Type: Application
    Filed: December 23, 2019
    Publication date: April 30, 2020
    Applicants: Merck Sharp & Dohme Corp., Merck Sharp & Dohme B.V.
    Inventors: Amy M. Beebe, Jason Ka Jen Cheung, Veronica Juan, Laurence Fayadat-Dilman, Svetlana Sadekova, Jerelyn Wong, Hans van Eenennaam, Andrea van Elsas, Lars Guelen, Thierry Olivier Fischmann, Winifred W. Prosise
  • Purification Process for Removal of Tyrosine Sulfation Antibody Variants; Purified Compositions
    Publication number: 20200123251
    Abstract: The present invention relates to purified antibody and antigen-binding fragment compositions that lack sulfated tyrosine on one or more tyrosine residues in the immunoglobulin chains. Purification methods for removing sulfated tyrosine variants from antibody and antigen-binding fragment compositions are also provided.
    Type: Application
    Filed: October 26, 2017
    Publication date: April 23, 2020
    Applicant: Merck Sharp & Dohme Corp.
    Inventors: Jia Zhao, Sandra Rios, Svetlana Dukleska Schussler
  • Spirocyclic Pyridotriazine Derivatives useful as HIV integrase inhibitors
    Patent number: 10624912
    Abstract: The present invention relates to Spirocyclic Pyridotriazine Derivatives of Formula (I) and pharmaceutically acceptable salts thereof, wherein A, B, X, Y, R1, R2 and R10 are as defined herein. The present invention also relates to compositions comprising at least one Spirocyclic Pyridotriazine Derivative, and methods of using the Spirocyclic Pyridotriazine Derivatives for treating or preventing HIV infection in a subject.
    Type: Grant
    Filed: November 11, 2016
    Date of Patent: April 21, 2020
    Assignee: Merck Sharp & Dohme Corp.
    Inventors: Thomas H. Graham, Tao Yu, Sherman T. Waddell, John A. McCauley, Andrew Stamford, Wengsheng Liu, Jay A. Grobler, Libo Xu
  • Verification of data provenance for existing computer systems
    Patent number: 10628389
    Abstract: A proof of provenance system receives database logs from an existing system that does not natively provide data provenance verification. The system produces a local representation of the database (or a portion thereof). The system periodically or in response to another triggering event flattens the local representation of the database to generate an aggregated slice, which is stored in an aggregated slice store. A reduced representation of the aggregated slice (e.g., a hash or checksum) is determined and appended to a distributed ledger, such as a blockchain. The provenance of data from the existing system can then be verified by redetermining the reduced representation and comparing it to the version appended to the distributed ledger.
    Type: Grant
    Filed: January 25, 2018
    Date of Patent: April 21, 2020
    Assignee: Merck Sharp & Dohme Corp.
    Inventor: Jacob Ryan Bordens
  • CYCLIC DINUCLEOTIDE STING AGONISTS FOR CANCER TREATMENT
    Publication number: 20200113924
    Abstract: Therapies comprising administering at least one cyclic dinucleotide compound that activates the Stimulator of Interferon Genes (STING) pathway, and the use of such therapies in the treatment of cell-proliferation disorders such as cancer, are disclosed herein.
    Type: Application
    Filed: December 15, 2017
    Publication date: April 16, 2020
    Applicant: Merck Sharp & Dohme Corp.
    Inventors: Saso Cemerski, Jared N. Cumming, Lauren M. Flateland, Johnny E. Kopinja, Yanhong Ma, Samanthi A. Perera, Benjamin Wesley Trotter, Archie Ngai-Chiu Tse
  • COMPOSITIONS AND METHODS FOR TREATING CANCER WITH A COMBINATION OF AN ANTAGONIST OF PD-1 AND AN ANTI-CTLA4 ANTIBODY
    Publication number: 20200115451
    Abstract: The present invention relates to method for treating cancer comprising administering an antagonist of PD-1, e.g., anti-PD-1 antibody or antigen binding fragment thereof, and an anti-CTLA4 antibody or antigen binding fragment thereof, wherein the CTLA4 antibody or antigen binding fragment thereof is given at a fixed dose. Also provided are compositions and kits comprising a dosage of an anti-PD-1 antibody and a dosage of an anti-CTLA4 antibody, and uses thereof.
    Type: Application
    Filed: March 28, 2018
    Publication date: April 16, 2020
    Applicant: Merck Sharp & Dohme Corp.
    Inventors: Blanca Homet Moreno, Nageatte Ibrahim, Scot W. Ebbinghaus, Lokesh Jain, Scott Diede
  • Process for making phosphoramidate protected nucleoside compounds
    Patent number: 10618926
    Abstract: The present invention is directed to process for making Compounds of Formula (II): (II), and salts thereof, wherein B, X, R2, R3, R4 R7, R8 and R9 are defined herein.
    Type: Grant
    Filed: March 28, 2016
    Date of Patent: April 14, 2020
    Assignee: Merck Sharp & Dohme
    Inventors: Steven M. Silverman, Bryon Ladd Simmons, Zhuqing Liu, Jing Liao, Artis Klapars, Kevin R. Campos, Ana Inés Bellomo Peraza
  • Anti-TIGIT antibodies
    Patent number: 10618958
    Abstract: The present invention relates to anti-TIGIT antibodies, as well as use of these antibodies in the treatment of diseases such as cancer and infectious disease.
    Type: Grant
    Filed: November 20, 2017
    Date of Patent: April 14, 2020
    Assignee: Merck Sharp & Dohme Corp.
    Inventors: Sybil M. G. Williams, Drake LaFace, Laurence Fayadat-Dilman, Gopalan Raghunathan, Linda Liang, Wolfgang Seghezzi
  • Process for preparing formulations for gastrointestinal-targeted therapies
    Patent number: 10617650
    Abstract: The present invention provides a process for preparing enterically-coated lyospheres comprising a therapeutic agent comprising: a.) providing lyospheres comprising the therapeutic agent; b.) coating said lyospheres with an enteric polymer coating composition; and c.) isolating said enterically-coated lyospheres. In other embodiments, the invention provides dosage forms comprising a lyosphere comprising an effective amount of a therapeutic agent and an enteric polymer coating. In some embodiments, the therapeutic agent in the process or dosage form is a polypeptide, a protein, a peptide, a lipopeptide, a glycoprotein, a fusion protein, a protein conjugate, a cytokine, an enzyme, an antibody, an oligonucleotide, a vaccine vector, small molecule, a live virus, an inactivated virus, a virus-like particle, a viral protein subunit, an adjuvant, microbiome, a prebiotic, a probiotic, or an ectobiotic.
    Type: Grant
    Filed: October 11, 2016
    Date of Patent: April 14, 2020
    Assignee: Merck Sharp & Dohme Corp.
    Inventors: Akhilesh Bhambhani, Robert K. Evans, Pranav Gupta, Ronald L. Smith, Donna M. Williams
  • Processes for the preparation of a BACE inhibitor
    Patent number: 10618892
    Abstract: This invention provides an improved processes for the preparation of verubecestat (Compound of Formula (I)), a potent inhibitor of BACE-1 and BACE-2.
    Type: Grant
    Filed: February 10, 2017
    Date of Patent: April 14, 2020
    Assignee: Merck Sharp & Dohme Corp.
    Inventors: William J. Morris, David Thaisrivongs, Thomas W. Lyons
  • 5-(PYRIDIN-3-YL)OXAZOLE ALLOSTERIC MODULATORS OF THE M4 MUSCARINIC ACETYLCHOLINE RECEPTOR
    Publication number: 20200109137
    Abstract: The present invention is directed to 5-(pyridine-3-yl)oxaxole compounds which are allosteric modulators of the M4 muscarinic acetylcholine receptor. The present invention is also directed to uses of the compounds described herein in the potential treatment or prevention of neurological and psychiatric disorders and diseases in which M4 muscarinic acetylcholine receptors are involved. The present invention is also directed to compositions comprising these compounds. The present invention is also directed to uses of these compositions in the potential prevention or treatment of such diseases in which M4 muscarinic acetylcholine receptors are involved.
    Type: Application
    Filed: June 22, 2018
    Publication date: April 9, 2020
    Applicant: Merck Sharp & Dohme Corp.
    Inventors: Jianming BAO, Timothy J. HENDERSON, Chunsing LI, Michael Man-Chu LO, Robert D. Mazzola, Jr., Meng NA, Michael T. RUDD, David M. TELLERS, Ling TONG
  • Scoring methods for anti-PD therapy eligibility and compositions for performing same
    Patent number: 10613092
    Abstract: Aspects of the present disclosure provide methods for determining the eligibility of a subject having a malignancy for treatment with an anti-PD therapeutic agent based on a Combined Positive Score (CPS) for a tumor tissue sample from the subject. Compositions and kits or performing the disclosed methods are also provided.
    Type: Grant
    Filed: February 1, 2017
    Date of Patent: April 7, 2020
    Assignees: Agilent Technologies, Inc., Merck Sharp & Dohme Corp.
    Inventors: Karina Kulangara, Nancy Zhang, David Stanforth, Greg Angelides, Stephanie Waldroup, Kenneth Emancipator
  • METHODS FOR THE TREATMENT AND PROPHYLAXIS OF HIV AND AIDS
    Publication number: 20200101098
    Abstract: The present invention is directed to methods for inhibition of HIV reverse transcriptase, treatment of infection by HIV, prophylaxis of infection by HIV, and the treatment, prophylaxis and/or delay in the onset or progression of AIDS or ARC by administering a compound of structural Formula I or a pharmaceutically acceptable salt or co-crystal thereof, wherein X is —F or —Cl, less frequently than once daily.
    Type: Application
    Filed: December 11, 2019
    Publication date: April 2, 2020
    Applicant: Merck Sharp & Dohme Corp.
    Inventors: Daria Hazuda, Michael D. Miller, Jay A. Grobler, Deborah Anne Nicoll-Griffith
  • NOVEL SUBSTITUTED N'-HYDROXYCARBAMIMIDOYL-1,2,5-OXADIAZOLE COMPOUNDS AS INDOLEAMINE 2,3-DIOXYGENASE IDO INHIBITORS
    Publication number: 20200102278
    Abstract: Disclosed herein is a compound of formula (I), or a pharmaceutically acceptable salt thereof. Also disclosed herein are uses of the compounds disclosed herein in the potential treatment or prevention of an IDO-associated disease or disorder. Also disclosed herein are compositions comprising a compound disclosed herein. Further disclosed herein are uses of the compositions in the potential treatment or prevention of an IDO-associated disease or disorder.
    Type: Application
    Filed: March 23, 2018
    Publication date: April 2, 2020
    Applicant: Merck Sharp & Dohme Corp.
    Inventors: Liangqin Guo, Yongxin Han, Kun Liu, Shuwen He, Joseph Kozlowski, Ravi Nargund, Wensheng Yu, Hongjun Zhang, Qinglin Pu, Derun Li, Abdelghani Achab, Guoqing Li
  • C5-C6-oxacyclic fused iminothiadiazine dioxide compounds bearing an ether linker as BACE inhibitors, compositions, and their use
    Patent number: 10604534
    Abstract: In its many embodiments, the present invention provides certain C5-C6-oxacyclic fused iminothiadiazine dioxide compounds bearing an ether linker, including compounds Formula (I): or a tautomer thereof, and pharmaceutically acceptable salts of said compounds and said tautomers, wherein RN, R1, R2, RA, ring A, ring C, and m are as defined herein. The novel compounds of the invention are useful as BACE inhibitors and/or for the treatment and prevention of various pathologies related thereto. Pharmaceutical compositions comprising one or more such compounds (alone and in combination with one or more other active agents), and methods for their preparation and use, including for the possible treatment of Alzheimer's disease, are also disclosed.
    Type: Grant
    Filed: February 6, 2017
    Date of Patent: March 31, 2020
    Assignee: Merck Sharp & Dohme Corp.
    Inventors: Shawn P. Walsh, Jared N. Cumming, Xing Dai
  • Pharmaceutical compositions containing doravirine, tenofovir disoproxil fumarate and lamivudine
    Patent number: 10603282
    Abstract: The instant invention relates to pharmaceutical compositions comprising doravirine, tenofovir disoproxil fumarate and lamivudine. These compositions are useful for the treatment of HIV infection. Also disclosed are processes for making said pharmaceutical compositions.
    Type: Grant
    Filed: November 29, 2016
    Date of Patent: March 31, 2020
    Assignee: Merck Sharp & Dohme Corp.
    Inventors: Santipharp Panmai, Aditya Tatavarti, Andrew M. Farrington, Varsha Biyyala, Leonardo R. Allain, Marcela Nefliu, Gerard R. Klinzing, Jie Ren, Matthew Lamm
  • TREATING INFECTIONS WITH CEFTOLOZANE/TAZOBACTAM IN SUBJECTS HAVING IMPAIRED RENAL FUNCTION
    Publication number: 20200093803
    Abstract: Disclosed are methods of administering cephalosporin/tazobactam to human patients with end stage renal disease undergoing hemodialysis and suffering from a complicated intra-abdominal infection or a complicated urinary tract infection.
    Type: Application
    Filed: July 29, 2019
    Publication date: March 26, 2020
    Applicant: MERCK SHARP & DOHME CORP.
    Inventors: Gopal KRISHNA, Gurudatt CHANDORKAR, Elham HERSHBERGER, Benjamin MILLER, Alan XIAO
  • NOVEL SUBSTITUTED SULFOXIMINE COMPOUNDS AS INDOLEAMINE 2,3-DIOXYGENASE (IDO) INHIBITORS
    Publication number: 20200095212
    Abstract: Compounds of Formula I, or a pharmaceutically acceptable salt, solvate or hydrate thereof: (I). Also disclosed herein are uses of the compounds disclosed herein in the potential treatment or prevention of an IDO-associated disease or disorder. Also disclosed herein are compositions comprising a compound disclosed herein. Further disclosed herein are uses of the compositions in the potential treatment or prevention of an IDO-associated disease or disorder.
    Type: Application
    Filed: February 19, 2018
    Publication date: March 26, 2020
    Applicant: Merck Sharp & Dohme Corp.
    Inventors: Kun Liu, Dane Clausen, Liangqin Guo, Yongxin Han, Shuwen He, Joseph Kozlowski, Derun Li, Qinglin Pu, Wensheng Yu, Hongjun Zhang
  • 6,5-FUSED HETEROARYL PIPERIDINE ETHER ALLOSTERIC MODULATORS OF THE M4 MUSCARINIC ACETYLCHOLINE RECEPTOR
    Publication number: 20200095261
    Abstract: The present invention is directed to 6,5-fused heteroarylpiperidine ether compounds which are allosteric modulators of the M4 muscarinic acetylcholine receptor. The present invention is also directed to uses of the compounds described herein in the potential treatment or prevention of neurological and psychiatric disorders and diseases in which M4 muscarinic acetylcholine receptors are involved. The present invention is also directed to compositions comprising these compounds. The present invention is also directed to uses of these compositions in the potential prevention or treatment of such diseases in which M4 muscarinic acetylcholine receptors are involved.
    Type: Application
    Filed: December 18, 2017
    Publication date: March 26, 2020
    Applicant: Merck Sharp & Dohme Corp.
    Inventors: Xiaolei GAO, Sandra L. KNOWLES, Chunsing LI, Michael Man-Chu LO, Robert D. MAZZOLA, JR., Debra L. ONDEYKA